Astellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from US biotech Pandion Therapeutics with potential in the treatment of type 1 ...

The partnership will help podiatry and specialty care providers improve efficiency and access tailored solutions that ...

ROCHESTER, N.Y.--(BUSINESS WIRE)--Pandion Optimization Alliance, a premier Group Purchasing Organization (GPO) harnessing the collective power of our customers for value and savings, celebrated ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation for autoimmune diseases and ...

If you want Merck to snap you up for nearly $2 billion, all you have to do is play hardball. That’s according to a new Securities and Exchange Commission (SEC) filing from the Big Pharma, which ...

Pandion, a parcel logistics network that sought to solve the “middle mile” of e-commerce residential delivery, shuttered operations abruptly last Friday. Founder and CEO Scott Ruffin, who was also the ...

Pandion Therapeutics is still in the earliest stage of testing its lead drug candidate in humans, but Merck sees enough potential for the biotech’s approach to autoimmune disease to plunk down $1.85 ...

WATERTOWN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs ...

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Taylor Soper on Mar 22, 2024 at 7:10 ...

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Todd Bishop on Jan 10, 2025 at 2:38 ...

Merck said Thursday it agreed to acquire Pandion Therapeutics, a clinical-stage biotech firm developing products for patients with autoimmune diseases, in a deal valued at $1.85 billion, amid hopes ...